Cellebrite DI (NASDAQ:CLBT) CRO Marcus Jewell Sells 9,928 Shares of Stock

Cellebrite DI Ltd. (NASDAQ:CLBT – Get Free Report) CRO Marcus Jewell sold 9,928 shares of the business’s stock in a transaction that occurred on Tuesday, November 17th. The shares were sold at an average price of $10.66, for a total value of $105,832.48. Following the completion of the sale, the executive owned 404,345 shares in the company, valued at $4,310,317.70. The trade was a 2.40% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Marcus Jewell also recently made the following trade(s):

  • On Monday, November 16th, Marcus Jewell sold 12,462 shares of Cellebrite DI stock. The stock was sold at an average price of $11.55, for a total transaction of $143,936.10.
  • On Thursday, November 12th, Marcus Jewell sold 393 shares of Cellebrite DI stock. The shares were sold at an average price of $13.31, for a total value of $5,230.83.
  • On Friday, August 21st, Marcus Jewell sold 12,562 shares of Cellebrite DI stock. The stock was sold at an average price of $11.24, for a total value of $141,196.88.

Cellebrite DI Trading Down 4.2%

NASDAQ CLBT opened at $10.65 on Wednesday. The firm’s fifty day moving average price is $11.58 and its two-hundred day moving average price is $13.17. The firm has a market capitalization of $2.66 billion, a P/E ratio of 44.38, a price-to-earnings-growth ratio of 1.41 and a beta of 1.06. Cellebrite DI Ltd. has a 1 year low of $9.58 and a 1 year high of $19.39.

Institutional Trading of Cellebrite DI

A number of institutional investors have recently bought and sold shares of the company. Nine Ten Capital Management LLC grew its stake in Cellebrite DI by 19.8% during the second quarter. Nine Ten Capital Management LLC now owns 4,126,808 shares of the company’s stock worth $60,251,000 after purchasing an additional 682,933 shares during the period. Wellington Management Group LLP lifted its stake in shares of Cellebrite DI by 93.7% in the second quarter. Wellington Management Group LLP now owns 3,049,904 shares of the company’s stock valued at $44,529,000 after buying an additional 1,475,579 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Cellebrite DI by 14.7% during the 1st quarter. Renaissance Technologies LLC now owns 2,860,639 shares of the company’s stock valued at $39,420,000 after purchasing an additional 365,700 shares during the last quarter. Portolan Capital Management LLC boosted its position in shares of Cellebrite DI by 1.8% during the third quarter. Portolan Capital Management LLC now owns 1,967,445 shares of the company’s stock valued at $22,153,000 after buying an additional 34,931 shares during the last quarter. Finally, Weiss Asset Management LP grew its stake in shares of Cellebrite DI by 3,485.3% in the 1st quarter. Weiss Asset Management LP now owns 1,899,841 shares of the company’s stock worth $26,180,000 after acquiring an additional 1,846,851 shares in the last quarter. Institutional investors own 45.88% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Lake Street Capital reduced their price objective on shares of Cellebrite DI from $21.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, August 14th. Needham & Company LLC raised their price objective on Cellebrite DI from $12.50 to $14.00 and gave the stock a “buy” rating in a research note on Thursday, November 12th. Weiss Ratings upgraded shares of Cellebrite DI from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday. DA Davidson reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Cellebrite DI in a research note on Tuesday, September 15th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Cellebrite DI from $16.00 to $15.00 and set an “overweight” rating on the stock in a research note on Friday, November 13th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Cellebrite DI presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.75.

Get Our Latest Research Report on CLBT

About Cellebrite DI

(Get Free Report)

Cellebrite DI Ltd. develops digital intelligence software and services that help organizations access, collect, preserve and analyze digital evidence. Its tools are used to investigate information from mobile devices, computers, cloud sources and other digital systems. The company’s offerings include its UFED platform for extracting data from digital devices, Physical Analyzer for examining and interpreting evidence, and analytics and case-management tools such as Pathfinder and Guardian. Customers include law enforcement, public safety, intelligence and defense agencies, as well as organizations in the private sector.

See Also

Insider Buying and Selling by Quarter for Cellebrite DI (NASDAQ:CLBT)

Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.